Hepion (HEPA) Back in the Spotlight, Gains 230% in May.
Hepion (HEPA) Phase 2 ‘ALTITUDE-NASH’ Trial Achieves Primary and Secondary Endpoints, Including Improvement in Liver Function and Multiple NASH Biomarkers.
Definitely NOT for traders or...
And we Have Another Triple! Ardelyx (ARDX) Touches $5.00, up 333%.
LIVE QUOTE
Ardelyx Enters the Danger Zone* With Tenapanor.
The company produced favorable (albeit very technical) information (data) at the National Kidney Foundation 2023 Spring Clinical...
Tsunami of Business Headed Pressure Bio’s (PBIO) Way?
We think there is a potential Tsunami of business headed towards Pressure Bio over then next 3-5 years. And well beyond.
As the chart...
Latest article
Latest Research Report: $20 Price Target from Greenridge Global.
Here are four research reports below to peruse, all with price targets $20.00 or more...
While we don't issue price targets, it's comforting to see...
Three More Companies Suspended by SEC!
Millions of Investor's Dollars are Being Trapped.
These three companies had a combined market cap of $563 million at the time they were halted, whose...
AI Data Center Short – Jim Chanos
“If the economic life on these things is three years ... the whole economics of a lot of these deals kind of falls...
